JW Life Science

JW Life Science Gross Margin

The Gross Margin of JW Life Science (234080.KS) as of Nov 11, 2026 is 28.05 %. In the previous year, Gross Margin was 25.85 % — a change of 8.51% (higher).

Gross Margin

28.05 %

YoY

8.51%

Last updated:

Gross Margin of JW Life Science is 2025 28.05 % . Gross Margin of JW Life Science was 2024 25.85 % . It decreases by 8.51% higher compared to the previous year.

For JW Life Science, the gross margin of 28.0% is broadly stable versus 28.9% a few years ago.

The JW Life Science Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
32.61 KRW
Jan 1, 2019
28.55 KRW
Jan 1, 2020
32.42 KRW
Jan 1, 2021
28.95 KRW
Jan 1, 2022
33.39 KRW
Jan 1, 2023
32.84 KRW
Jan 1, 2024
25.85 KRW
Jan 1, 2025
28.05 KRW
The JW Life Science Gross Margin history
YEARGross MarginYoY
28.05 %+8.51%
25.85 %-21.28%
32.84 %-1.65%
33.39 %+15.33%
28.95 %-10.71%
32.42 %+13.54%
28.55 %-12.43%
32.61 %-3.07%
33.64 %+29.81%
25.91 %+8.29%
23.93 %+7.82%
22.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JW Life Science Stock analysis

What does JW Life Science do? JW Life Science Corp. manufactures intravenous fluids including basic IV fluids with water, electrolytes, and glucose, nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals, and special infusion solutions for specific medical cases. The company produces total parenteral nutrition (TPN) products as part of its manufacturing focus. The primary buyers of these products are healthcare providers and hospitals requiring intravenous treatments for patient care. The company serves the medical sector by providing essential fluid and nutrition solutions for clinical use. The firm's product segments are defined by the types of IV fluids and TPN solutions they produce, targeting healthcare institutions that administer intravenous therapies. Basic IV fluids are used for general hydration and electrolyte balance, while nutrient infusion solutions support patient nutrition in critical care settings. Special infusion solutions address unique medical conditions requiring tailored treatments. The company's offerings are integral to hospital and clinic operations in delivering patient care. JW Life Science Corp. generates revenue through the sale of its manufactured intravenous fluid products to healthcare facilities. The company's business model relies on consistent demand for IV fluids and TPN solutions within the medical industry. Its products are distributed to hospitals and clinics that require these essential medical supplies for patient treatment protocols. JW Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JW Life Science stock

Gross Margin of JW Life Science is 28.05 % in 2025.

Gross Margin of JW Life Science changed from 25.85 % to 28.05 %, representing a 8.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin JW Life Science since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's JW Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — JW Life Science

All Key Metrics — JW Life Science